<DOC>
	<DOCNO>NCT00148486</DOCNO>
	<brief_summary>To demonstrate efficacy dose-response NS 2330 versus placebo patient early Parkinson 's Disease 14 week treatment , investigate safety tolerability NS 2330 patient .</brief_summary>
	<brief_title>A Fourteen-Week Placebo-Controlled Dose-Response Efficacy Safety Study NS 2330 Early Parkinson 's Disease Patients ( Study Proof Concept Early Parkinson 's Disease Triple Reuptake Inhibitor , NS 2330 / SCEPTRE )</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Parkinson 's disease &lt; 5 year , nondemented , &lt; 6 month levodopa none trial . Off levodopa , DA agonists , psychotropics 30 day screen . Amantadine , anticholinergic allow stable dosage . Hoehn &amp; Yahr stage IIII . Depression allow , chronic disease unstable might interfere ability participate .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>